【摘要】 目的:对精神分裂症患者服用奥氮平的血药浓度进行监测,观察临床疗效与血药浓度之间的关系。方法:65例精神分裂症患者,单用奥氮平治疗8周;采用高效液相色谱法(HPLC)监测血药浓度,同时记录剂量、疗效和不良反应。结果:奥氮平剂量5～25 mg,血药浓度为3.0～86.0μg/L,平均(25.5±13.5)μg/L,药物剂量与血药浓度呈正相关(r=0.582)。血药浓度<10μg/L者13例,10～20μg/L者43例,>20μg/L者9例,其显效率分别为5例(38.5%)、33例(76.7%)和6例(66.7%)。<10μg/L与>10μg/L的显效率以后者显著较高(P<0.05);而10～20μg/L与>20μg/L之间差异无显著性(P>0.05)。血药浓度<10μg/L有2例(15.0%),10～20μg/L有23例(53.0%),>20μg/L有8例(89.0%)发生了不良反应,3组比较差异有显著性(P<0.01)。结论:奥氮平治疗精神分裂症的血药浓度以10～20μg/L较为适宜,疗效较好,不良反应较少。更多还原

【Abstract】 Objective: To monitor the plasma concentration of olanzapine in patients with schizophrenia and investigate the relationship between clinical efficacy and plasma level of olanzapine. Method:65 patients with schizophrenia were treated with olanzapine for 8 weeks and the plasma concentration of olanzapine was measured by high performance liquid chromatography(HPLC),with doses of olanzapine,clinical efficacy and adverse effects being recorded. Results:The plasma concentration of olanzapine was 3.0 μg/L to 86.0 μg/L when patients took olanzapine 5~25 mg/day.There was a positive relationship between olanzapine doses and the plasma concentration(r=0.582).13 patients had plasma concentration<10 μg/L,43 patients in range of 10~20 μg/L and 9 patients>20 μg/L,with response rate 38.5%(5 cases),76.7%(33 cases) and 66.7%(6 cases),respectively.The patients with plasma concentration of olanzapine>10 μg/L had higher response rate compared with those<10 μg/L(P<0.05).However,there was no significant difference in the response rate between patients with plasma concentration in range of 10~20 μg/L and that>20 μg/L(P>0.05).Significant differences appeared in adverse effects among the three groups,with 2 patients(15.0%) in<10μg/L group,23 patients(53.0%) in range of 10~20 μg/L group and 8 patients(89.0%)in>20 μg/L group(P<0.01). Conclusion:The plasma concentration of olanzapine in range of 10~20 μg/L was suitable for the treatment of schizophrenia,with better efficacy and less adverse effects.更多还原